PF-Atlas › Clinical Trials › NCT05408910

Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis

Rifaximin 550 MG Oral Tablet [XIFAXAN] · Phase 2

Registry ID
NCT05408910
Phase
Phase 2
Status
Withdrawn
Drug / intervention
Rifaximin 550 MG Oral Tablet [XIFAXAN]
Sponsor
Wake Forest University Health Sciences
Start
2025-07

About this trial

Rifaximin 550 MG Oral Tablet [XIFAXAN] is evaluated in NCT05408910, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Wake Forest University Health Sciences. Current status: Withdrawn.

View NCT05408910 on ClinicalTrials.gov →

Explore related

All Rifaximin 550 MG Oral Tablet [XIFAXAN] trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT05408910 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.